Treatment of MDA-MB-231 breast cancer cells with Dasatinib or PP2 resulted in elevated levels of p-c-Fos (Ser374 and Ser32) and compared to total c-Fos levels, which remained unchanged (Figure 2A). This evidence concerns the gene FOS and breast carcinoma.